90.21
-0.65%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Suzhou Zelgen Biopharmaceuticals Co
Its shares trade on Shanghai under the ticker 688266.SS. It has been listed since 23 January 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥812.7m and a net loss of CN¥160.7m. At that date it held total assets of CN¥2.97bn and shareholders' equity of CN¥1.08bn.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-01-23. The firm's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The firm operates in the domestic market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jan 2020
- Employees
- 843
- Website
- zelgen.com ↗
Leadership
Pay as last reported
- Mr. Zelin ShengChairman of the Board, General Manager, since 2019CN¥1.9m
- Mr. Gang HuangFinance Director, Deputy General ManagerCN¥841,300
- Ms. Zegi ShengChief Scientific OfficerCN¥2.0m
- Ms. Qingping GaoDeputy General Manager, Secretary of the BoardCN¥995,200
- Ms. Huiping LuExecutive Deputy General Manager, Director, since 2019CN¥1.2m
- Mr. Jisheng WuDeputy General Manager, Director, since 2019CN¥2.0m
- Mr. Binhua LuDeputy General ManagerCN¥1.7m
- Mr. Liqing WuVice President of MedicineCN¥1.2m
- Mr. Bin ZhangExecutive Director of Biological R&DCN¥839,300
- Mr. Min LiDirector
- Ms. Ping WuDirector
- Mr. Yiming WuDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Suzhou Zelgen Biopharmaceuticals employs 843 full-time employees for research and development.
- The company's main products target tumors, bleeding, and blood diseases effectively.
- Suzhou Zelgen operates in both domestic and overseas markets for pharmaceutical distribution.
Weaknesses
- The company's IPO date was 23 January 2020, indicating limited market history.
- Suzhou Zelgen focuses on pharmaceuticals and intermediates without diversification.
- The firm's headquarters in Suzhou may limit access to global talent pools.
Opportunities
- Expanding into immune inflammatory diseases and hepatobiliary diseases markets.
- Growing demand for new medications in the Health Care sector globally.
- Increasing market share in the domestic Chinese pharmaceutical market.
Threats
- Competition from established biotechnology firms in the Health Care sector.
- Regulatory challenges in overseas markets for pharmaceutical products.
- Economic downturns affecting global pharmaceutical industry investments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.